Alternative Gene Expression S.L., a biotechnology company, engages in the research, development, and production of recombinant pharmaceutical products. The company focuses on developing vaccines and vaccine technologies, therapeutic molecules, and diagnostic reagents. It offers subunit recombinant vaccines against various animal and human pathogens, such as rabbit hemorrhagic virus diseases, porcine circovirus, bovine viral diarrhea, human papilloma virus, and influenza virus. The company also provides diagnostic proteins for serological diagnosis of animal infectious diseases, which include African swine fever, rabbit haemorrhagic disease, porcine respiratory and reproductive syndrome, infectious bovine rhinotraqueitis, west nile, and hepatitis E; and therapeutic antibodies for rotavirus infection and viral internalization inhibitors. In addition, it involves in developing antigen tetramerization protein scaffold, antigen targeting to APCs, particulated-encapsulated vaccines, and antiviral drugs. The company was founded in 2005 and is based in Madrid, Spain.